利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.045 秒)

    Methods and compositions for treatment of bone defects with placental cell populations
    8.
    发明授权
    Methods and compositions for treatment of bone defects with placental cell populations 有权
    用于治疗胎盘细胞群体骨缺损的方法和组合物

    公开(公告)号：US08728805B2

    公开(公告)日：2014-05-20

    申请号：US12546556

    申请日：2009-08-24

    申请人： Sascha D. Abramson ,  Marian Guelakis ,  Mohammad A. Heidaran ,  Kristen Labazzo ,  Shmuel Yaccoby

    发明人： Sascha D. Abramson ,  Marian Guelakis ,  Mohammad A. Heidaran ,  Kristen Labazzo ,  Shmuel Yaccoby

    IPC分类号： C12N5/07

    CPC分类号： A61K35/50 ,  A61K35/12 ,  C12N5/0605

    摘要： Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.

    摘要翻译： 本文提供了成骨胎盘贴壁细胞（OPAC），使用OPAC和OPAC群体的方法，以及培养，增殖，扩增或分化OPAC的方法。 本文还提供了使用OPAC来配制适于给予受试者的可植入或可注射组合物的方法。 本文还提供了用OPAC和包含OPAC的组合物治疗骨缺损的方法。 本文还提供了在多发性骨髓瘤的治疗和管理中使用OPAC的方法，例如减少多发性骨髓瘤个体中多发性骨髓瘤的一种或多种症状的进展，停止进展或改善多发性骨髓瘤的一种或多种症状的方法，包括施用多个 的OPACs给个人。

    Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations
    9.
    发明申请
    Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations 有权
    用胎盘细胞群治疗骨缺损的方法和组合

    公开(公告)号：US20100047214A1

    公开(公告)日：2010-02-25

    申请号：US12546556

    申请日：2009-08-24

    申请人： Sascha D. Abramson ,  Marian Guelakis ,  Mohammad A. Heidaran ,  Kristen Labazzo ,  Shmuel Yaccoby

    发明人： Sascha D. Abramson ,  Marian Guelakis ,  Mohammad A. Heidaran ,  Kristen Labazzo ,  Shmuel Yaccoby

    IPC分类号： A61K35/50 ,  C12N5/071

    CPC分类号： A61K35/50 ,  A61K35/12 ,  C12N5/0605

    摘要： Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.

    摘要翻译： 本文提供了成骨胎盘贴壁细胞（OPAC），使用OPAC和OPAC群体的方法，以及培养，增殖，扩增或分化OPAC的方法。 本文还提供了使用OPAC来配制适于给予受试者的可植入或可注射组合物的方法。 本文还提供了用OPAC和包含OPAC的组合物治疗骨缺损的方法。 本文还提供了在多发性骨髓瘤的治疗和管理中使用OPAC的方法，例如减少多发性骨髓瘤个体中多发性骨髓瘤的一种或多种症状的进展，停止进展或改善多发性骨髓瘤的一种或多种症状的方法，包括施用多个 的OPACs给个人。

    Hydrazide compounds with angiogenic activity
    10.
    发明申请
    Hydrazide compounds with angiogenic activity 有权
    具有血管生成活性的酰肼化合物

    公开(公告)号：US20050118227A1

    公开(公告)日：2005-06-02

    申请号：US11001250

    申请日：2004-12-01

    申请人： Joachim Kohn ,  Kristen Labazzo ,  Durgadas Bolikal

    发明人： Joachim Kohn ,  Kristen Labazzo ,  Durgadas Bolikal

    IPC分类号： A61K31/785 ,  A61K38/10 ,  A61L27/34 ,  A61L27/58

    CPC分类号： A61L27/58 ,  A61K31/785 ,  A61L27/34 ,  Y10T428/31507 ,  Y10T428/31725 ,  Y10T428/31786 ,  Y10T428/31855 ,  Y10T428/31971

    摘要： Compounds exhibiting angiogenic properties incorporating the structure of Formula I: R3—NH—NH—C(═O)—R2—P—R1  (I) wherein P is a water-soluble, biodegradable polymer, R1 is hydrogen, lower alkyl, lower alkoxy or —R2—C(═O)—NH—NH—R3; each R2 is independently —CH2—, —NH— or O; and each R3 is independently hydrogen or a residue of a naturally occurring alpha-L-amino acid or dipeptide thereof. Polymer networks crosslinked with hydrazide compounds are also disclosed, together with implantable medical devices incorporating the compounds and crosslinked polymers, and angiogenesis-promoting treatment methods, including wound-treatment methods.

    摘要翻译： 表现出结合式I结构的血管生成特性的化合物：<？in-line-formula description =“In-line formula”end =“lead”→R 3 -NH-NH-C（ - O）-R 2 -PR 1（I）<？in-line-formula description =“In-line formula”end =“tail”？>其中P是 水溶性，可生物降解的聚合物，R 1是氢，低级烷基，低级烷氧基或-R 2 -C（-O）-NH-NH-R > 3 ; 每个R 2独立地是-CH 2 - ， - NH-或O; 并且每个R 3独立地是氢或天然存在的α-L-氨基酸或其二肽的残基。 还公开了与酰肼化合物交联的聚合物网络，以及结合有化合物和交联聚合物的可植入医疗装置，以及包括伤口治疗方法在内的血管生成促进治疗方法。